Efalizumab for Patients With Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial
CONTEXT Because T-cell interactions are involved in the pathophysiology of psoriasis, therapy with a T-cell modulator may have beneficial effects on psoriasis severity and health-related quality of life (HRQL). OBJECTIVE To assess the efficacy and safety of efalizumab, a T-cell modulator, in patient...
Saved in:
Published in | JAMA : the journal of the American Medical Association Vol. 290; no. 23; pp. 3073 - 3080 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Chicago, IL
American Medical Association
17.12.2003
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | CONTEXT Because T-cell interactions are involved in the pathophysiology of psoriasis,
therapy with a T-cell modulator may have beneficial effects on psoriasis severity
and health-related quality of life (HRQL). OBJECTIVE To assess the efficacy and safety of efalizumab, a T-cell modulator,
in patients with plaque psoriasis. DESIGN, SETTING, AND PATIENTS Phase 3 randomized, double-blind, parallel-group, placebo-controlled
trial involving 556 adult patients with stable, moderate to severe plaque
psoriasis and conducted at 30 study centers in the United States and Canada
between January and July 2002. INTERVENTIONS Patients were randomly assigned in a 2:1 ratio to receive 12 weekly
doses of subcutaneous efalizumab, 1 mg/kg (n = 369), or placebo equivalent
(n = 187). MAIN OUTCOME MEASURES At least 75% improvement on the Psoriasis Area and Severity Index (PASI-75);
improvement on the overall Dermatology Life Quality Index (DLQI), Itching
Visual Analog Scale (VAS), and Psoriasis Symptom Assessment (PSA) at week
12 vs baseline. RESULTS Efalizumab-treated patients experienced significantly greater improvement
on all end points than placebo-treated patients. Twenty-seven percent of efalizumab-treated
patients achieved PASI-75 vs 4% of the placebo group ( P<.001). Efalizumab-treated patients exhibited significantly greater
mean percentage improvement than placebo-treated patients on the overall DLQI
(47% vs 14%; P<.001), Itching VAS (38% vs −0.2%; P<.001), and PSA frequency and severity subscales (48%
vs 18% and 47% vs 17%, respectively; P<.001 for
both) at the first assessment point. Efalizumab was safe and well tolerated,
with primarily mild to moderate adverse events. CONCLUSION In this 12-week study, efalizumab resulted in significant improvements
in clinical end points, including physician-assessed and dermatology-specific
patient-reported HRQL measures, in patients with moderate to severe plaque
psoriasis. |
---|---|
ISSN: | 0098-7484 1538-3598 |
DOI: | 10.1001/jama.290.23.3073 |